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Abstract 
 
Low weight at birth associates with subsequent susceptibility to diabetes. Epigenetic 
modulation is among the mechanisms potentially mediating this association. We performed a 
genome-wide DNA methylation analysis in placentas from term infants born appropriate-for-
gestational-age (AGA) or small-for-gestational-age (SGA), to identify new genes related to 
fetal growth and neonatal body composition. Candidate genes were validated by bisulfite 
pyrosequencing (30 AGA, 21 SGA) and also analyzed in cord blood. Gene expression 
analyses were performed by RT-PCR. Neonatal body composition was assessed by dual X-
ray absorptiometry at age 2 weeks. The ATG2B, NKX6.1 and SLC13A5 genes (respectively 
related to autophagy, beta-cell development and function, and lipid metabolism) were 
hypermethylated in placenta and cord blood from SGA newborns, whereas GPR120 (related 
to free fatty acid regulation) was hypomethylated in placenta and hypermethylated in cord 
blood. Gene expression levels were opposite to methylation status, and both correlated with 
birth weight, with circulating IGF-I, and with total and abdominal fat at age 2 weeks. In 
conclusion, alterations in methylation and expression of genes involved in the regulation of 
energy homeostasis were found to relate to fetal growth and neonatal body composition, and 
may thus be among the early mechanisms modulating later susceptibility to diabetes. 
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Individuals born small-for-gestational age (SGA) are at increased risk for developing 
insulin resistance, obesity, metabolic syndrome and, subsequently, cardiovascular disease and 
type 2 diabetes in adulthood (1,2). Growth restraint before birth is thought to confer such risk, 
particularly when followed by excessive weight gain after birth (3). By the postnatal age of 4 
months, SGA infants already have an altered endocrine-metabolic profile with elevated 
concentrations of circulating IGF-I and high-molecular-weight (HMW) adiponectin (4). These 
abnormalities are influenced by early nutrition and evolve towards a profile with more hepatic 
and visceral adiposity in childhood (5). The mechanisms underpinning these abnormalities 
remain poorly understood.  
Epigenetic regulation of the placenta evolves during pre-implantation and progresses 
further during gestation. Strictly regulated DNA methylation has a key role in tissue-specific 
gene regulation and transcription; DNA methylation in CpG islands has been so far the most 
investigated target (6). Although DNA methylation has traditionally been viewed as an 
epigenetic “silencing” mark, recent advances suggest that the impact of DNA methylation on 
gene expression depends more on the genomic location of the CpG site (7). An adverse 
intrauterine environment can modify placental epigenetic marks and gene expression profiles, 
resulting in fetal growth restraint (8-10). Differential patterns of placental and cord blood 
methylation and/or expression have been described in selected imprinted and non-imprinted 
genes (11,12) in heterogeneous populations, including preterm infants (11) and growth-
restricted fetuses from pregnancies complicated by hypertension or pre-eclampsia (12). 
Genome-wide methylation abnormalities in adipose-derived stem cells from SGA individuals 
have also been reported (13). 
Here, we tested whether placental and cord blood methylation and/or expression of 
genes involved in the regulation of energy homeostasis (which may influence both early 
growth and later diabetes risk) differ between offspring born appropriate-for-gestational-age 
(AGA) or born SGA after an uncomplicated, term, singleton pregnancy.  
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Research Design and Methods 
Study population 
The study cohort consisted of 51 mother-placenta-newborn trios, with postnatal 
follow-up (Supplemental Figure 1). Thirty infants were born AGA (17 girls, 13 boys) and 21 
SGA (9 girls, 12 boys). The inclusion and exclusion criteria are detailed as Online 
Supplemental Material. 
Maternal age at conception, parity and height, as well as pre-gestational weight and body 
mass index [BMI, weight (Kg)/height (m2)], were retrieved from clinical records. Gestational 
age was calculated by last menses and confirmed by first-trimester ultrasound (∼10 wk).  
The infant’s weight and length were measured by the same investigator (GS) at birth and 
at the postnatal age of approximately 2 weeks. Weight was measured with a beam balance 
(Seca, Hamburg, Germany) and length with a length board, using the mean of three 
measurements.   
 
DNA methylation microarray in placenta 
DNA methylation profiling was performed in 8 AGA and 8 SGA samples with the 
Agilent DNA Methylation array (ID 049738, Agilent Technologies), which examines 27,800 
highly informative CpG sites located within the proximal promoter regions of 14,475 genes. 
Nearly 100% of these CpG sites were localized within CpG islands. The process for isolating 
methylated DNA from purified DNA samples, and labelling and hybridization to Human 
DNA Methylation Array was conducted following the manufacturer’s protocol (Agilent 
Microarray Analysis of Methylated DNA Immunoprecipitation v 1.1, Agilent Technologies). 
Briefly, 5µg of purified DNA was sonicated in PBS; DNA fragments were run in a 1.5% 
agarose gel and ranged from 200 to 1000 bp. Enrichment of methylated regions was 
performed using an antibody against methylcytosine. Enriched and unenriched DNAs were 
labelled with Cy3 and Cy5, respectively, and hybridized in the microarray. The microarray 
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chip was then washed and immediately scanned using a Microarray Scanner (Model G2505C, 
Agilent Technologies). 
 
Gene expression analysis in placenta and cord blood by quantitative real time in differentially 
methylated genes validated by pyrosequencing 
Steady state mRNA levels of GPR120, ATG2B, NKX6-1 and SLC13A5, and the 
housekeeping gene GAPDH were measured using gene-specific primers: GPR120: forward 
5’-CTGCCTCTCTGCGTCTTCTT-3’, reverse 5’-CTCTTGCATCCAGGAGGTGT-3’; 
ATG2B: forward 5’-ATCCCAGCCTTTTGAAGGAC-3’, reverse 5’-
AGCAAAAGCAGTGGGTTGAT-3’; NKX6-1: forward 5’- CTTCTGGCCCGGAGTGAT-
3’, reverse 5’-CCCGCCAAGTATTTTGTTTG-3’; SLC13A5: forward 5’- 
CCTGCTGGATTGGAA GGTAA-3’, reverse 5’-CACTCAGTGAACACGGCAAC-3’; 
GAPDH: forward 5’-GTCAGTGGTGGACCTGACCT-3’, reverse 5’-
TGCTGTAGCCAAATTCGTTG-3) and SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA). PCR reactions were performed using a 7500 Real-Time PCR 
System (Applied Biosystems), by mixing 1 µl of cDNA (20 ng) with 24 µl of reaction mixture 
(14 µl 2X SYBR Green I Master Mix buffer, 2 µl forward primer (2.5 µM); 2 µl reverse 
primer (2.5 µM), and 6 µl of nuclease-free water. Relative expression was then calculated 
according to the 2-∆Ct method (14). 
The details involving cord blood and placenta collection, DNA extraction and 
modification, microarray data pre-processing, validation by bisulfite pyrosequencing, RNA 
extraction and retro-transcription, as well as the Assays & Neonatal Body Composition 
procedures are provided as Online Supplemental Material.  
 
Statistics and ethics 
Statistical analyses were performed using SPSS software 23.0 (Inc. Chicago, IL). 
Unpaired t-test was used to study differences between AGA and SGA subgroups. Correlation 
Page 5 of 43 Diabetes
6 
 
and stepwise multiple regression analysis were used to study the associations between 
methylation status and expression levels in placenta and cord blood, and auxological and body 
composition parameters. Covariance analysis was used to adjust for sex, gestational age, type 
of delivery and pre-gestational BMI. The level of significance was set at P<0.05. 
The study was approved by the Institutional Review Board of Hospital Sant Joan de 
Déu at Barcelona University; written informed consent was obtained before delivery. 
 
Results 
Maternal and offspring characteristics 
Table 1 summarizes the anthropometric parameters in the mothers and newborns by 
birth weight subgroups. The delivery rate by caesarian section was not different between the 
AGA and SGA subgroups (13% vs 19%, respectively). SGA infants displayed lower 
circulating levels of insulin and IGF-I in cord blood, and less fat and lean mass at age 2 
weeks, as expected, while their mothers were shorter, and had a lower pre-gestational weight 
and BMI (14). 
 
Gene Ontology & Functional Pathway Analysis 
We identified n=409 genes differentially methylated in SGA newborns (FDR < 0.1) 
(Supplemental Table 1). The GO analysis disclosed that most of them were involved in the 
regulation of metabolic processes, DNA binding and transcription, and biosynthesis of 
macromolecules (Supplemental Table 2).  The KEGG software identified enriched numbers 
of epigenetic changes in n=11 canonical pathways, the most significant being those related to 
cell development and function, lipid metabolism, autophagy and signalling (Table 2). The 
top-ranked hyper- and hypomethylated genes in these pathways (n=39) are listed in 
Supplemental Tables 3 and 4. Since validation of all 39 genes by pyrosequencing was not 
feasible (costly and technically complex), we selected – in accordance with the study 
purpose– those genes (n=8) which were relevant to the regulation of glucose and lipid 
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metabolism; of those, three were hypomethylated (MAPK8IP1, CAMK4 and GPR120) and 
five were hypermethylated (ATG2B, KLF11, NKX6.1, NRIP1 and SLC13A5) in placentas of 
SGA newborns (Supplemental Tables 3 & 4). 
 
Differentially methylated genes in placenta and cord blood 
 Validation of DNA methylation patterns by pyrosequencing demonstrated that 
ATG2B, NKX6.1 and SLC13A5 were hypermethylated in SGA placenta (respectively P<0.02, 
P<0.008 and P<0.0001 vs AGA) and SGA cord blood (all P<0.0001), while GPR120 was 
hypomethylated in SGA placenta (P=0.0006) and hypermethylated in SGA cord blood 
(P<0.0001) (Figures 1 and 2). The differences in methylation were maintained after adjusting 
for sex, gestational age, type of delivery, and pre-gestational BMI. Pyrosequencing analysis 
failed to demonstrate differences in methylation status in MAPK8IP1, CAMK4, KLF11 and 
NRIP1 genes.  
 
Expression of the validated genes in placenta and cord blood 
 Expression levels of ATG2B, NKX6.1, SLC13A5 and GPR120 in placenta and cord 
blood were opposite to their methylation status (all P ≤ 0.004 in placenta; and all P≤0.01 in 
cord blood) (Figures 1 and 2). The differences in gene expression were maintained after 
adjusting for sex, gestational age, type of delivery, and pre-gestational BMI. 
Correlation and multiple regression analyses between genetic and endocrine-metabolic 
data are provided as Online Supplemental Data. 
 
Discussion 
We identified differential methylation profiles in placenta and cord blood from SGA 
infants in 18 CpG sites along the ATG2B, NKX6.1, SLC13A5 and GPR120 genes – all non-
imprinted – and report for the first time associations with birth weight, endocrine-metabolic 
markers and neonatal body composition. Neither differences in methylation and expression, 
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nor associations with growth and endocrine-metabolic markers were attributable to 
differences in gestational age or maternal BMI, or to sex or delivery route. The finding that 
the methylation and the expression of highlighted genes do mirror each other, as well in 
placenta as in cord blood, suggests that the expression of those genes is mainly under 
epigenetic control which, in turn, is presumably controlled by multiple maternal and 
environmental factors, most of which remain to be identified.  
 Hypermethylation and down-regulation of ATG2B (autophagy-related 2B) in placenta 
and cord blood was associated with smaller size at birth and lower fat mass. Autophagy is 
critical in the maintenance of maternal-fetal material exchange during placental development, 
in survival immediately after birth (15) and in cell differentiation, including in adipogenesis 
(16). In SGA infants, decreased autophagy resulting from down-regulation of ATG2B – and 
thus compromising nutrient supply – could be among the mechanisms accounting for prenatal 
growth restraint.  
NKX6.1 (NKX6 homeodomain 1) – a transcription factor known to be involved in 
pancreatic differentiation and β cell homeostasis – was hypermethylated and down-regulated 
in placenta and cord blood from SGA infants, and associated with birth weight and neonatal 
fat mass. In the pancreas, NKX6.1 is exclusively expressed in β cells, and is required for 
prenatal β cell development and function and postnatal β cell expansion (17). In placenta, it 
remains to be studied whether the epigenetically controlled expression of NKX6.1 is a 
modulator of nutrient transfer, and thus perhaps an indirect modulator of fetal β cell 
development, insulin secretion and fat mass.  
 Mammalian Indy homologue (SLC13A5, mIndy) encodes for a sodium-coupled citrate 
transporter (NaCT) that is mainly expressed in hepatocytes, and serves as a link between 
carbohydrate catabolism and lipogenesis. Loss of SLC13A5 augments energy expenditure and 
hepatic fat oxidation, and attenuates hepatic lipogenesis, reducing overall growth (18). 
SLC13A5 was hypermethylated and down-regulated in SGA placenta and cord blood. These 
findings align well with the knowledge that SGA infants are less adipose and more insulin 
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sensitive than AGA infants, not only in early infancy but also – if breastfed – in late infancy 
(19). Reduced expression of SLC13A5 may conceivably be a programming mechanism 
attempting to protect those fetuses from excessive fat accumulation and impaired insulin 
action early during spontaneous catch-up. 
 GPR120 (G-protein coupled receptor 120), also known as free fatty acid receptor 4 
(FFAR4), is a lipid sensor that regulates whole-body energy homeostasis in humans and 
rodents, mediating insulin sensitizing effects in vivo by repressing inflammation (20). 
GPR120 activation indirectly stimulates pancreatic insulin secretion by inducing the release 
of glucagon-like-peptide-1 from the gut (21). Here, GPR120 was found to be hypomethylated 
and hyperexpressed in SGA placenta. The human placenta expresses GPR120 mainly in the 
microvillous membrane of the syncytiotrophoblast (22) where it presumably transfers 
unsaturated long-chain fatty acids from the maternal circulation into the syncytiotrophoblast, 
rather than into the fetal circulation. In contrast, GPR120 was hypermethylated and 
hypoexpressed in cord blood of SGA infants, who have a reduced fat mass across early 
infancy (4). Interestingly, in the critical window of adipogenesis, GPR120 is thought to be a 
key contributor to adipocyte differentiation (23).   
 This preliminary study is the first to associate epigenetic settings of non-imprinted 
genes to size at birth and to markers of endocrine-metabolic homeostasis and neonatal body 
composition in healthy term AGA and SGA infants. Study limitations include the small 
sample size, the lack of adjustment for cell composition in placenta/cord blood (24), the 
influence of maternal genetics on placental gene expression, the potential underrepresentation 
of differential methylation in CpG islands (25), and the inability to obtain - for ethical 
reasons- target tissues for assessing tissue-specific DNA methylation/expression. The 
strengths include the strict inclusion criteria (leading to distinct AGA and SGA populations, 
and avoiding perinatal confounders), and the parallel assessments of placenta/cord blood 
pairs.  
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 In conclusion, in SGA placenta and cord blood, we identified differential methylation 
and expression patterns of genes involved in the regulation of glucose homeostasis and lipid 
metabolism. These epigenetic variations may influence fetal growth, early body composition, 
and lifelong diabetes risk.   
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Figure legends 
 
Figure 1  
Methylation (top) and expression levels (bottom) of validated genes in placentas from 
infants born appropriate (AGA, n=30) or small-for-gestational age (SGA, n=21). Values are 
mean ± SEM. 
ATG2B, NKX6.1 and SLC13A5 were hypermethylated, whereas GPR120 was 
hypomethylated in SGA infants. Expression levels of ATG2B, NKX6.1, SLC13A5 and 
GPR120 were opposite to their methylation status. 
*P<0.05; **P<0.01; ***P<0.0001 vs AGA. 
 
Figure 2 
Methylation (top) and expression levels (bottom) of validated genes in cord blood from 
infants born appropriate (AGA, n=30) or small-for-gestational age (SGA, n=21). Values are 
mean ± SEM. 
ATG2B, NKX6.1, SLC13A5 and GPR120 were hypermethylated in SGA infants. Expression 
levels of ATG2B, NKX6.1, SLC13A5 and GPR120 were opposite to their methylation status. 
*P<0.05; **P<0.01; ***P<0.0001. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 13 of 43 Diabetes
14 
 
Table 1. Auxological and clinical parameters in the studied subjects and in their mothers 
 
 
 AGA SGA P value 
Mothers N=30 N=21  
Age (yr) 31.8 ± 1.1 31.8 ± 1.0 ns 
Height (cm)    164 ± 0.01   159 ± 0.01 0.01 
Weight (Kg) 66.0 ± 2.6  53.6 ± 1.6 0.0005 
BMI (Kg/m2) 24.6 ± 0.9  21.1 ± 0.6 0.003 
Pregnancy weight gain (Kg) 13.4 ± 0.9  11.5 ± 0.7 ns 
Primiparous (%) 57 76 ns 
Caesarean section (n, %) 4 (13) 4 (19) ns 
Singleton Newborns N=30 N=21  
Gender (% female) 57 43 ns 
Gestational age (wk)    40.2 ± 0.2      38.7 ± 0.3 0.0008 
Birth Weight (Kg)      3.3 ± 0.1        2.3 ± 0.1 <0.0001 
Birth Weight Z-score  0.1 ± 0.1  -2.3 ± 0.1 <0.0001 
Birth Length (cm)    50.6 ± 0.3  45.6 ± 0.5 <0.0001 
Birth Length Z-score  0.2 ± 0.1  -1.9 ± 0.2 <0.0001 
Placental weight (Kg)  0.60 ± 0.02   0.51 ± 0.03 0.022 
Endocrine-metabolic variables at birth  
Glucose (mmol/L) 4.4 ± 0.2  4.5 ± 0.4 ns 
Insulin (pmol/L)    27.8 ± 3.5    17.36 ± 2.1 0.009 
IGF-I (nmol/L) 0.09 ± 0.01  0.06 ± 0.01 0.001 
HMW adiponectin (mg/L) 43 ± 3  41 ± 3 ns 
Body composition at 2 wk    
Weight Gain since Birth (g)      184 ± 53  310 ± 60 ns 
Length Gain since Birth (cm)  1.7 ± 0.2   2.2 ± 0.6 ns 
Bone Mineral Density (g/cm2)  0.27 ± 0.01  0.24 ± 0.01   0.026 
Bone Mineral Content (g) 94.4 ± 2.2  69.9 ± 2.8 <0.0001 
Fat Mass (%) 18 ± 1 16 ± 1   0.04 
Fat Mass (g) 696 ± 39  467 ± 38   0.0001 
Abdominal Fat (%) 4.1 ± 0.2 3.3 ± 0.2   0.01 
Abdominal Fat (g) 29 ± 2  16 ± 3   0.0007 
Lean Mass (%) 82 ± 1 83 ± 1  ns 
Lean Mass (g)    3110 ± 55      2279 ± 68 <0.0001 
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Data are mean ± SEM. BMI: body mass index; IGF-I: insulin-like growth factor-I; HMW 
adiponectin: high-molecular weight adiponectin. 
Page 15 of 43 Diabetes
16 
 
Table 2. Differentially methylated genes involved in KEGG pathways. Pathways are arranged (top to bottom), according to P value. 
The genes in bold (n=39) display the lowest (top-ranked) individual P values. 
 
 
 
 
 
 
Canonical Pathway P-value Methylation status Gene Symbol 
Cell development and function 3.7E-04 Hyper PHOX2B, NDEL1, GFOD1, SMAD7,KCNK13, EFNA1, CHRM2, CNTN4, NKX2-5, NKX3-2, NKX6-1, LMO2, PYGO2 
Lipid metabolism 4.0E-04 Hypo SOAT1, LYPLA2P1, GPR120, SORL1, MAPK8IP1, ECHDC2, PEX1, LYPLA2, ATG2B, HSD17B4 
Autophagy 5.4E-04 Hyper DRAM1, ATG2B, AMBRA1, SOGA1 
Cellular signalling 6.6E-04 Hypo EIF2AK1, SLK, CAMK4, MAPK13, PAK4, CHKB, PRKG1, ALK, STARD3NL, PAPSS1, AKT3 
Cation channel activity 1.3E-03 Hyper CALHM2,SCN3B, SLC24A2, SLC13A5, KCNK13 
Regulation of immunity 1.7E-03 Hyper STAT5B, ICOSLG, PTPN22, RARA 
Endoplasmic reticulum 
metabolism 
2.4E-03 Hyper 
SOAT1, DERL2, SPTLC1, CLSTN2, LOC729316, RTN2, SYNE1, NDEL1, LRP10, LARGE, C3ORF57, FAM156A, GNAS, FAM156B, EIF2AK1, 
POM121C, KPNA4, EDA, DLG1 
DNA-binding 2.4E-03 Hypo 
FLYWCH1, HIST1H2B1, HIST4H4, HIST1H4K, LOC100045887, NFKB2, SRF, GM11275, ARNT, HOXA3, LOC674678, HIST1H4A, 
HIST1H4B, NKX3-2, POU3F4, SRRM1, HIST1H4F, HIST1H4C, HIST1H4D, HIST1H4I, LBR, HIST1H4J, HIST1H4H, ZBTB48, CEBPD, 
NEUROG1, ZFP3, MECOM, HIST2H4, UHRF2, SFPQ, TOP3B 
Transcription regulation 3.2E-03 Hyper 
ZNF583, POU6F2, STAT5B, ZNF827, RHOQ, HSBP1, CNOT4, ZNF343, ZGPAT, GTF2H2C, BRPF1, ZNF182, 
ZNF436, GTF2H2C, ZNF680, ZFP90, PSMC3IP, RARA, SOX17, FOXB1, GATAD1, MBD3L1, PHOX2B,  RCOR3 
Transcription regulation 3.2E-03 Hypo 
SCAI, JUNB, MCM5, NRIP1, GTF2H2B, ZNF500, ZNF234, TAF11, PRDM9, MED18, LIN54, EDA, HMX3, ZNF468, 
GPBP1L1, SCML1, NFYC, MYBL1, HOXA1, THAP1, NKX2-5, MLLT3, SMAD7, KLF11, SOX30, TFCP2,STAT1, 
FOXP4, NKX6-1, ZNF22, ZNF212, DR1, NARFL, FMR1, SFPQ, TOP3B 
Apoptosis 3.7E-03 Hyper FAM176A, DOCK1, LTBR, AIMP2, STAG3L3, FAM82A2, KLF11, PAK1 
Protein-interaction 8.4E-03 Hyper DOCK1, DOCK5, ABI1, SKAP2, EPS8L1, RASA1, DLG1 
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Figure 1 
Gene Methylation in Placenta 
Gene Expression in Placenta 
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Figure 2 
Gene Methylation in Cord Blood 
Gene Expression in Cord Blood 
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Mother-Newborn Pairs  
(Jan 2012 - Dec 2014) 
N=7431 
N=267 (142 girls, 125 boys) 
 
SGA  
N=21 (9 girls, 12 boys)   
 
Supplemental Figure 1.  
Recruitment of the study population. 
AGA: appropriate for gestational age 
SGA: small for gestational age 
AGA  
N=30 (17 girls, 13 boys)  
Placenta & cord blood collected for 
research purposes (logistic restraints)  
Inclusion & Exclusion Criteria  
(see Methods) 
Co-availability of  
maternal, placental and neonatal data  
and postnatal follow-up 
N=163 (85 girls, 78 boys) 
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Supplemental Table 1. Differentially methylated genes ranked by P value between AGA and SGA subgroups.  
Q values, coefficients of regression (R
2
) and the variation are also shown. 
                        
                        * Selected genes for validation by pyrosequencing. 
 
 
Gene Symbol    Gene Denomination 
P 
value 
Q 
value 
R
2
 Variation 
 
NKX6-1* 1 NK6 homeobox 1 0.0002 0.012 0.68 12.73 
 
HIST1H2BI 2 Histone cluster 1, H2bi 0.0002 0.012 0.88 12.70 
 
UHRF2  3 Ubiquitin-like with PHD and ring finger domains 2, E3 ubiquitin protein ligase 0.0003 0.012 0.87 33.37 
 
MAPK8IP1* 4 Mitogen-activated protein kinase 8 interacting protein 1 0.0004 0.012 0.87 18.74 
 
CAMK4* 5 Calcium/calmodulin-dependent protein kinase IV 0.0004 0.012 0.83 15.36 
 
CHRM2 6 Cholinergic receptor, muscarinic 2 0.0008 0.012 0.84 25.24 
 
TOP3B 7 Topoisomerase (DNA) III beta 0.001 0.012 0.80 15.55 
 
STARD3NL 8 STARD3 N-terminal like 0.001 0.012 0.79 32.32 
 
LMO2 9 LIM domain only 2 (rhombotin-like 1) 0.001 0.012 0.82 24.88 
 
ATG2B* 10 Autophagy related 2B 0.002 0.012 0.78 28.79 
 
MLLT3 11 Myeloid/lymphoid or mixed-lineage leukemia: translocated to, 3 0.002 0.012 0.89 11.96 
 
CLSTN2 12 Calsyntenin 2 0.002 0.012 0.79 28.42 
 
EIF2AK1 13 Eukaryotic translation initiation factor 2-alpha kinase 1 0.002 0.012 0.78 15.72 
 
SFPQ 14 Splicing factor proline/glutamine-rich 0.002 0.012 0.78 18.80 
 
KLF11* 15 Kruppel-like factor 11 0.003 0.012 0.75 24.82 
 
SLC13A5* 16 Sodium-dependent citrate transporter), member 5 0.003 0.012 0.75 24.62 
 
NRIP1* 17 Nuclear receptor interacting protein 1 0.003 0.012 0.74 15.46 
 
ZNF500 18 Zinc finger protein 500 0.003 0.012 0.76 15.58 
 
DOCK5 19 Dedicator of cytokinesis 5 0.003 0.012 0.75 26.43 
 
GPR120* 20 Free fatty acid receptor 4 0.003 0.012 0.75 29.63 
 
GFOD1 21 Glucose-fructose oxidoreductase domain containing 1 0.004 0.012 0.73 21.74 
 
LRP10 23 Low density lipoprotein receptor-related protein 10 0.004 0.012 0.73 26.22 
 
GTF2H2C 24 General transcription factor IIH, polypeptide 2C 0.004 0.012 0.73 42.19 
 
PYGO2 25 Pygopus family PHD finger 2 0.004 0.012 0.73 17.30 
 
PEX1 26 Peroxisomal biogenesis factor 1 0.004 0.012 0.74 12.73 
 
PRKG1 27 Protein kinase, cGMP-dependent, type I 0.004 0.012 0.74 50.29 
 
NKX3-2 28 NKX3 homeobox 2 0.004 0.012 0.72 24.89 
 
ZGPAT 29 Zinc finger, CCCH-type with G patch domain 0.005 0.012 0.72 26.03 
 
KCNK13 30 Potassium channel, subfamily K, member 13 0.005 0.012 0.71 20.44 
 
SOGA1 31 Suppressor of glucose, autophagy associated 1 0.005 0.012 0.71 11.73 
 
MAPK13 32 Mitogen-activated protein kinase 13 0.005 0.012 0.72 18.27 
 
CALHM2 33 Calcium homeostasis modulator 2 0.006 0.012 0.85 9.22 
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 SKAP2 34 Src kinase associated phosphoprotein 2 0.006 0.012 0.70 27.46 
 
KPNA4 35 Karyopherin alpha 4 (importin alpha 3) 0.006 0.012 0.69 16.52 
 
FMR1 36 Fragile X mental retardation 1 0.007 0.012 0.68 16.67 
 
NKX2-5 37 NKX2 homeobox 5 0.008 0.012 0.85 23.80 
 
ZNF182 38 Zinc finger protein 182 0.008 0.012 0.68 16.27 
 
ZNF436 39 Zinc finger protein 436 0.008 0.012 0.65 49.76 
 
ICOSLG 40 Inducible T-cell co-stimulator ligand 0.008 0.012 0.66 16.62 
 
RASL12 41 RAS like family 12 0.01 0.012 0.76 23.22 
 
ATP6V1F 42 ATPase H+ Transporting V1 Subunit F 0.01 0.012 0.69 20.60 
 
RNF38 43 Ring Finger Protein 38 0.01 0.012 0.68 17.65 
 
ZNF789 44 Zinc Finger Protein 789 0.01 0.012 0.68 40.11 
 
HCG11 45 HLA Complex Group 11 (Non-Protein Coding) 0.01 0.012 0.68 21.58 
 
LBR 46 Lamin B receptor 0.01 0.012 0.80 14.86 
 
EMID1 47 EMI domain containing 1 0.01 0.012 0.76 23.34 
 
BAMBI 48 BMP and  activin membrane-bound  inhibitor 0.01 0.012 0.74 49.69 
 
RUSC2 49 Run and SH3 domain containing 2 0.01 0.012 0.74 28.64 
 
MARC1 50 Mithocondrial amidoxime reducing component 1 0.01 0.012 0.73 21.71 
 
PDZRN4 51 PDZ domain containing ring finger 4 0.01 0.012 0.72 16.24 
 
TMCO1 52 Transmembrane and coiled-coil domains 0.01 0.012 0.71 16.94 
 
AKR1E2 53 Aldo-Keto reductase family 1, member E2 0.01 0.012 0.71 20.85 
 
SMAD7 54 SMAD Family Member 7 0.01 0.012 0.54 24.32 
 
NDEL1 55 NudE Neurodevelopment Protein 1 Like 1 0.01 0.012 0.51 24.17 
 
HSD17B7P2 56 Hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 0.01 0.012 0.71 17.59 
 
WIPF2 57 WAS/WASL interacting protein family member 2 0.01 0.012 0.71 33.71 
 
PRDM9 58 PR domain 9 0.01 0.012 0.71 10.96 
 
WIPI2 59 WD repeat domain, phosphoinositide interacting 2 0.01 0.012 0.70 26.85 
 
ATP1B1 60 ATPase Na+/K+ Transporting Subunit Beta 1 0.01 0.012 0.70 20.72 
 
DNLZ 61 DNL-Type Zinc Finger 0.01 0.012 0.70 15.78 
 
FLRT2 62 Fibronectin Leucine Rich Transmembrane Protein 2 0.01 0.012 0.69 24.44 
 
NRSN1 63 Neurensin 1 0.01 0.012 0.69 26.33 
 
SERBP1 64 SERPINE1 mRNA Binding Protein 1 0.01 0.012 0.68 18.85 
 
LIPT2 65 Lipoyl(Octanoyl) Transferase 2 (Putative) 0.01 0.012 0.68 30.22 
 
ZDHHC17 66 Zinc Finger DHHC-Type Containing 17 0.01 0.012 0.68 27.09 
 
ZBTB48 67 Zinc Finger And BTB Domain Containing 48 0.01 0.012 0.68 17.20 
 
MPND 68 MPN Domain Containing 0.01 0.012 0.67 11.79 
 
NOVA1 69 Neuro-Oncological Ventral Antigen 1 0.01 0.012 0.67 14.76 
 
PSME1 70 Proteasome Activator Subunit 1 0.01 0.012 0.67 41.36 
 
SNX12 71 Sorting Nexin 12 0.01 0.012 0.66 28.08 
 
AKT3 72 V-Akt Murine Thymoma Viral Oncogene Homolog 3 0.01 0.012 0.66 24.74 
 
STX18 73 Syntaxin 18 0.01 0.012 0.66 36.29 
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 SHANK2 74 SH3 And Multiple Ankyrin Repeat Domains 2 0.01 0.012 0.66 34.90 
 
EFNA1 75 Ephrin A1 0.01 0.012 0.66 30.52 
 
C3ORF55 76 PQ Loop Repeat Containing 2-Like 0.01 0.012 0.66 12.22 
 
CNTN4 77 Contactin 4 0.01 0.012 0.51 43.43 
 
HOXA1 78 Homeobox A1 0.01 0.012 0.48 23.60 
 
CA10 79 Carbonic Anhydrase 10 0.01 0.012 0.65 24.60 
 
CDC14A 80 Cell Division Cycle 14A 0.01 0.012 0.65 33.53 
 
IDS 81 Iduronate 2-Sulfatase 0.01 0.012 0.65 11.50 
 
KIAA1274 82 Phosphatase Domain Containing, Paladin 1 0.01 0.012 0.59 25.16 
 
KLHL5 83 Kelch Like Family Member 5 0.01 0.012 0.65 28.40 
 
SOAT1 84 Sterol O-Acyltransferase 1 0.01 0.012 0.57 34.02 
 
REXO1L2P 85 RNA exonuclease 1 Homolog-like 2 0.01 0.012 0.79 38.17 
 
PSMC3IP 86 PSMC3 interacting protein 0.01 0.012 0.70 16.88 
 
JUNB 87 Jun B Proto-Oncogene 0.01 0.012 0.65 26.19 
 
CBLN3 88 Cerebellin 3 Precursor 0.01 0.012 0.65 48.79 
 
WDR82 89 WD Repeat Domain 82 0.01 0.012 0.64 37.32 
 
SIKE1 90 Suppressor Of IKBKE 1 0.01 0.012 0.64 13.49 
 
RCOR3 91 REST Corepressor 3 0.01 0.012 0.64 42.14 
 
FAM98A 92 Family With Sequence Similarity 98 Member A 0.01 0.012 0.64 12.44 
 
ZNF451 93 Zinc Finger Protein 451 0.01 0.012 0.64 51.69 
 
MAGED2 94 MAGE Family Member D2 0.01 0.012 0.63 56.81 
 
SPTLC1 95 Serine Palmitoyltransferase Long Chain Base Subunit 1 0.01 0.012 0.63 11.35 
 
EIF2S3 96 Eukaryotic Translation Initiation Factor 2 Subunit Gamma 0.01 0.012 0.63 34.49 
 
RNF111 97 Ring Finger Protein 111 0.01 0.012 0.63 18.66 
 
PITPNC1 98 Phosphatidylinositol Transfer Protein, Cytoplasmic 1 0.01 0.012 0.63 19.85 
 
CNOT4 99 CCR4-NOT Transcription Complex Subunit 4 0.01 0.012 0.62 16.38 
 
LARGE 100 Like-Glycosyltransferase 0.01 0.012 0.62 20.47 
 
SCML1 101 Sex Comb On Midleg-Like 1 (Drosophila) 0.01 0.012 0.62 21.93 
 
SLED1 102 Proteoglycan 3 Pseudogene 0.01 0.012 0.62 32.95 
 
TSN 103 Translin 0.01 0.012 0.62 30.26 
 
STAT1 104 Signal Transducer And Activator Of Transcription 1 0.01 0.012 0.62 35.80 
 
STAT5B 105 Signal Transducer And Activator Of Transcription 5B 0.01 0.012 0.62 13.00 
 
GBAP1 106 Glucosylceramidase Beta Pseudogene 1 0.01 0.012 0.62 10.89 
 
SYK 107 Spleen Tyrosine Kinase 0.01 0.012 0.61 37.05 
 
SRF 108 Serum Response Factor 0.01 0.012 0.61 33.12 
 
ZNF766 109 Zinc Finger Protein 766 0.01 0.012 0.61 31.60 
 
SNORD24 110 Small Nucleolar RNA, C/D Box 24 0.01 0.012 0.61 25.53 
 
DUOX2 111 Dual Oxidase 2 0.01 0.012 0.61 13.24 
 
RRP12 112 Ribosomal RNA Processing 12 Homolog 0.01 0.012 0.61 46.87 
 
NTAN1 113 N-Terminal Asparagine Amidase 0.01 0.012 0.61 27.15 
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 PAK4 114 P21 Protein (Cdc42/Rac)-Activated Kinase 4 0.01 0.012 0.60 45.41 
 
POLQ 115 Polymerase (DNA) Theta 0.01 0.012 0.60 53.11 
 
SNORA16A 116 Small Nucleolar RNA, H/ACA Box 16A 0.01 0.012 0.60 43.91 
 
GNPDA2 117 Glucosamine-6-Phosphate Deaminase 2 0.01 0.012 0.60 13.90 
 
MGAT5B 118 Mannosyl (Alpha-1,6-)-Glycoprotein Beta-1,6-N-Acetyl-glucosaminyltransferase, Isozyme B 0.01 0.012 0.60 37.02 
 
LANCL3 119 LanC Like 3 0.01 0.012 0.60 11.23 
 
CPOX 120 Coproporphyrinogen Oxidase 0.01 0.012 0.60 16.32 
 
SLC35B2 121 Solute Carrier Family 35 Member B2 0.01 0.012 0.60 15.40 
 
RUNDC3A 122 RUN Domain Containing 3ª 0.01 0.012 0.60 20.99 
 
TMEM9B 123 TMEM9 Domain Family Member B 0.01 0.012 0.60 34.17 
 
ZFP90 124 ZFP90 Zinc Finger Protein 0.01 0.012 0.60 16.93 
 
ATP5E 125 ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Epsilon Subunit 0.01 0.012 0.59 28.49 
 
SDR39U1 126 Short Chain Dehydrogenase/Reductase Family 39U Member 1 0.01 0.012 0.59 49.63 
 
FBXO46 127 F-Box Protein 46 0.01 0.012 0.59 18.44 
 
ATP7B 128 ATPase Copper Transporting Beta 0.01 0.012 0.59 17.02 
 
CRCP 129 CGRP Receptor Component 0.01 0.012 0.59 34.37 
 
ASB7 130 Ankyrin Repeat And SOCS Box Containing 7 0.01 0.012 0.59 25.81 
 
UBA1 131 Ubiquitin Like Modifier Activating Enzyme  0.01 0.012 0.59 51.16 
 
RNF180 132 Ring Finger Protein 180 0.01 0.012 0.59 49.32 
 
C22ORF40 133 Cysteine Rich DPF Motif Domain Containing 1 0.01 0.012 0.59 23.01 
 
RSPO3 134 R-Spondin 3 0.01 0.012 0.59 10.53 
 
C1ORF174 135 Chromosome 1 Open Reading Frame 174 0.01 0.012 0.59 16.15 
 
ATG16L1 136 Autophagy Related 16 Like 1 0.01 0.012 0.59 43.09 
 
ZKSCAN2 137 Zinc Finger With KRAB And SCAN Domains 2 0.01 0.012 0.59 23.54 
 
BRPF1 138 Bromodomain And PHD Finger Containing 1 0.01 0.012 0.59 49.90 
 
PLEKHG6 139 Pleckstrin Homology And RhoGEF Domain Containing G6 0.01 0.012 0.59 37.44 
 
EIF3B 140 Eukaryotic Translation Initiation Factor 3 Subunit B 0.01 0.012 0.58 30.11 
 
BTBD9 141 BTB Domain Containing 9 0.01 0.012 0.58 27.97 
 
GPBP1L1 142 GC-Rich Promoter Binding Protein 1 Like 1 0.01 0.012 0.51 19.05 
 
SCN3B 143 Sodium Voltage-Gated Channel Beta Subunit 3 0.01 0.012 0.50 16.18 
 
PHOX2B 144 Paired Like Homeobox 2b 0.01 0.012 0.49 33.87 
 
TAF11 145 TATA-Box Binding Protein Associated Factor 11 0.01 0.012 0.49 15.13 
 
LYPLA2P1 146 Lysophospholipase II Pseudogene 1 0.01 0.013 0.68 18.79 
 
DRAM1 147 DNA Damage Regulated Autophagy Modulator 1 0.01 0.013 0.64 16.38 
 
AMBRA1 148 Autophagy  And  Beclin 1 Regulator 1 0.01 0.013 0.56 26.99 
 
PAPSS1 149 3'-Phosphoadenosine 5'-Phosphosulfate Synthase 1 0.01 0.012 0.47 30.81 
 
PTPN22 150 Protein Tyrosine Phosphatase, Non-Receptor Type 22 0.01 0.012 0.47 25.48 
 
LOC739216 151 POM121 Membrane Glycoprotein Pseudogene 0.01 0.013 0.61 33.16 
 
C3ORF57 152 Serine Palmitoyltransferase Small Subunit B 0.01 0.012 0.48 16.35 
 
FAM156B 153 Family With Sequence Similarity 156 Member B 0.01 0.013 0.50 19.01 
Page 23 of 43 Diabetes
 NFKB2 154 Nuclear Factor Kappa B Subunit 2 0.01 0.012 0.48 35.97 
 
HIST1H4B 155 Histone Cluster 1, H4b 0.01 0.013 0.58 17.91 
 
HIST1H4F 156 Histone Cluster 1, H4f 0.01 0.013 0.48 9.91 
 
HIST1H4C 157 Histone Cluster 1, H4c 0.01 0.013 0.62 21.32 
 
HIST1H4J 158 Histone Cluster 1, H4j 0.01 0.012 0.48 38.75 
 
HIST1H4H 159 Histone Cluster 1, H4h 0.01 0.013 0.47 22.21 
 
MCM5 160 Minichromosome Maintenance Complex Component 5 0.02 0.012 0.58 15.68 
 
FZD7 161 Frizzled Class Receptor 7 0.02 0.012 0.58 20.01 
 
TSTD1 162 Thiosulfate Sulfurtransferase Like Domain Containing 1 0.02 0.012 0.58 21.36 
 
SLK 163 STE20 Like Kinase 0.02 0.012 0.58 35.08 
 
SSR4 164 Signal Sequence Receptor, Delta 0.02 0.012 0.58 17.49 
 
TMEM86A 165 Transmembrane Protein 86ª 0.02 0.012 0.58 18.67 
 
CPEB4 166 Cytoplasmic Polyadenylation Element Binding Protein 4 0.02 0.012 0.58 27.96 
 
FAM125A 167 Multivesicular Body Subunit 12ª 0.02 0.012 0.58 42.16 
 
RTN2 168 Reticulon 2 0.02 0.012 0.58 25.53 
 
SLC35B3 169 Solute Carrier Family 35 Member B3 0.02 0.012 0.57 16.83 
 
RAB36 170 RAB36, Member RAS Oncogene Family 0.02 0.012 0.57 12.76 
 
ZNF333 171 Zinc Finger Protein 333 0.02 0.012 0.57 25.95 
 
PROCA1 172 Protein Interacting With Cyclin A1 0.02 0.012 0.57 13.60 
 
FAM64A 173 Family With Sequence Similarity 64 Member A 0.02 0.012 0.57 29.55 
 
GATAD1 174 GATA Zinc Finger Domain Containing 1 0.02 0.012 0.57 11.87 
 
FAM105A 175 Family With Sequence Similarity 105 Member A 0.02 0.012 0.57 35.87 
 
SNRPN 176 Small Nuclear Ribonucleoprotein Polypeptide N 0.02 0.012 0.57 24.56 
 
ADAMTS19 177 ADAM Metallopeptidase With Thrombospondin Type 1 Motif 19 0.02 0.012 0.57 16.11 
 
GRIK5 178 Glutamate Ionotropic Receptor Kainate Type Subunit 5 0.02 0.012 0.57 10.91 
 
ARNT 179 Aryl Hydrocarbon Receptor Nuclear Translocator 0.02 0.012 0.57 36.56 
 
GRID1 180 Glutamate Ionotropic Receptor Delta Type Subunit 1 0.02 0.012 0.57 12.37 
 
MB21D1 181 Mab-21 Domain Containing 1 0.02 0.012 0.57 39.38 
 
TSLP 182 Thymic Stromal Lymphopoietin 0.02 0.012 0.57 46.08 
 
USHBP1 183 USH1 Protein Network Component Harmonin Binding Protein 1 0.02 0.012 0.57 16.25 
 
ZNF680 184 Zinc Finger Protein 680 0.02 0.012 0.57 23.15 
 
POU3F4 185 POU Class 3 Homeobox 4 0.02 0.012 0.57 37.79 
 
STXBP5 186 Syntaxin Binding Protein 5 0.02 0.012 0.57 31.65 
 
FGF13 187 Fibroblast Growth Factor 13 0.02 0.012 0.57 11.40 
 
ZNF468 188 Zinc Finger Protein 761 0.02 0.012 0.57 13.89 
 
PALM2 189 PALM2-AKAP2 Readthrough 0.02 0.012 0.57 20.08 
 
VBP1 190 Von Hippel-Lindau Binding Protein 1 0.02 0.012 0.57 12.10 
 
RARA 191 Retinoic Acid Receptor Alpha 0.02 0.012 0.57 24.49 
 
LYPLA2 192 Lysophospholipase II 0.02 0.012 0.57 10.39 
 
PARVB 193 Parvin Beta 0.02 0.012 0.57 46.17 
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 RPL29 194 Ribosomal Protein L29 0.02 0.012 0.56 17.97 
 
RHOQ 195 Ras Homolog Family Member Q 0.02 0.012 0.56 43.80 
 
SOX30 196 SRY-Box 30 0.02 0.012 0.56 18.34 
 
CPNE1 197 Copine 1 0.02 0.012 0.56 11.73 
 
SIRPA 198 Signal Regulatory Protein Alpha 0.02 0.012 0.56 15.11 
 
IFT46 199 Intraflagellar Transport 46 0.02 0.012 0.56 22.43 
 
SRRM1 200 Serine And Arginine Repetitive Matrix 1 0.02 0.012 0.56 23.81 
 
SNTB1 201 Syntrophin Beta 1 0.02 0.012 0.56 10.84 
 
SLC39A10 202 Solute Carrier Family 39 Member 10 0.02 0.012 0.56 41.97 
 
GDI1 203 GDP Dissociation Inhibitor 1 0.02 0.012 0.56 12.34 
 
L3MBTL1 204 L(3)Mbt-Like 1 (Drosophila) 0.02 0.012 0.56 37.32 
 
TOMM34 205 Translocase Of Outer Mitochondrial Membrane 34 0.02 0.012 0.56 12.90 
 
METTL10 206 Methyltransferase Like 10 0.02 0.012 0.56 39.27 
 
ATF1 207 Activating Transcription Factor 1 0.02 0.012 0.56 38.04 
 
ZNF37BP 208 Zinc Finger Protein 37B, Pseudogene 0.02 0.012 0.55 23.84 
 
PIR 209 Pirin 0.02 0.012 0.55 45.71 
 
KCNMB3 210 Potassium Calcium-Activated Channel Subfamily M Regulatory Beta Subunit 3 0.02 0.012 0.55 27.69 
 
SLC41A3 211 Solute Carrier Family 41 Member 3 0.02 0.012 0.55 30.61 
 
HMGCLL1 212 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase-Like 1 0.02 0.012 0.55 18.78 
 
HMX3 213 H6 Family Homeobox 3 0.02 0.012 0.55 20.00 
 
PSMG1 214 Proteasome Assembly Chaperone 1 0.02 0.012 0.54 22.20 
 
PAK1 215 P21 Protein (Cdc42/Rac)-Activated Kinase 1 0.02 0.012 0.54 23.14 
 
KARS 216 Lysyl-TRNA Synthetase 0.02 0.012 0.54 9.48 
 
KRCC1 217 Lysine-Rich Coiled-Coil 1 0.02 0.012 0.54 29.83 
 
MIF 218 Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor) 0.02 0.012 0.54 21.57 
 
RLTPR 219 Capping Protein Regulator And Myosin 1 Linker 2 0.02 0.012 0.54 28.96 
 
POM121C 220 POM121 Transmembrane Nucleoporin C 0.02 0.012 0.54 29.62 
 
HSD17B4 221 Hydroxysteroid (17-Beta) Dehydrogenase 4 0.02 0.012 0.54 48.97 
 
DLG1 222 Discs Large Homolog 1, Scribble Cell Polarity Complex Component 0.02 0.012 0.54 15.34 
 
CHKB 223 Choline Kinase Beta 0.02 0.012 0.54 48.49 
 
TMEM14A 224 Transmembrane Protein 14A 0.02 0.012 0.54 27.31 
 
RPL21 225 Ribosomal Protein L21 0.02 0.012 0.54 18.54 
 
ZNF212 226 Zinc Finger Protein 212 0.02 0.012 0.54 34.36 
 
MID1IP1 227 MID1 Interacting Protein 1 0.02 0.012 0.54 79.31 
 
SCAI 228 Suppressor Of Cancer Cell Invasion 0.02 0.012 0.54 42.35 
 
CTTNBP2 229 Cortactin Binding Protein 2 0.02 0.012 0.54 23.97 
 
FAM197Y2P 230 Family With Sequence Similarity 197 Y-Linked Member 2, Pseudogene 0.02 0.012 0.54 25.33 
 
GABRA1 231 Gamma-Aminobutyric Acid Type A Receptor Alpha1 Subunit 0.02 0.012 0.54 33.41 
 
C2ORFf88 232 Chromosome 2 Open Reading Frame 88 0.02 0.013 0.54 24.80 
 
KDM4C 233 Lysine Demethylase 4C 0.02 0.012 0.54 34.59 
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 PEX3 234 Peroxisomal Biogenesis Factor  0.02 0.012 0.54 39.83 
 
PRPF4 235 Pre-MRNA Processing Factor 4 0.02 0.012 0.53 11.70 
 
CEBPD 236 CCAAT/Enhancer Binding Protein Delta 0.02 0.012 0.53 25.60 
 
NMT2 237 N-Myristoyltransferase 2 0.02 0.012 0.53 15.51 
 
FASTKD2 238 FAST Kinase Domains 2 0.02 0.012 0.53 25.78 
 
SLC4A1AP 239 Solute Carrier Family 4 Member 1 Adaptor Protein 0.02 0.012 0.53 26.36 
 
ENC1 240 Ectodermal-Neural Cortex 1 0.02 0.012 0.53 35.56 
 
RBM4B 241 RNA Binding Motif Protein 4B 0.02 0.012 0.53 12.36 
 
HLA-B 242 Major Histocompatibility Complex, Class I, B 0.02 0.012 0.53 49.40 
 
FANCB 243 Fanconi Anemia Complementation Group B 0.02 0.012 0.53 31.92 
 
MED18 244 Mediator Complex Subunit 18 0.02 0.012 0.53 13.64 
 
CBLN2 245 Cerebellin 2 Precursor 0.02 0.012 0.53 17.47 
 
NSUN4 246 NOP2/Sun RNA Methyltransferase Family Member 4 0.02 0.012 0.53 34.82 
 
ALK 247 Anaplastic Lymphoma Receptor Tyrosine Kinase 0.02 0.012 0.53 33.33 
 
HIST2H2BF 248 Histone Cluster 2, H2bf 0.02 0.012 0.53 21.72 
 
PUM1 249 Pumilio RNA Binding Family Member 1 0.02 0.012 0.53 32.92 
 
HIST4H4 250 Histone Cluster 4, H4 0.02 0.013 0.60 22.13 
 
HIST1H4K 251 Histone Cluster 1, H4k 0.02 0.012 0.48 51.75 
 
HIST1H4D 252 Histone Cluster 1, H4d 0.02 0.012 0.53 33.57 
 
HIST1H4I 253 Histone Cluster 1, H4i 0.02 0.013 0.56 11.50 
 
HIST2H4 254 Histone Cluster 4, H4 0.02 0.012 0.60 17.27 
 
NFYC 255 Nuclear Transcription Factor Y Subunit Gamma 0.02 0.012 0.47 28.13 
 
HOXA3 256 Homeobox A3 0.02 0.012 0.70 64.02 
 
NARFL 257 Nuclear Prelamin A Recognition Factor Like 0.02 0.013 0.50 58.32 
 
FAM176A 258 Eva-1 Homolog A, Regulator Of Programmed Cell Death 0.02 0.013 0.49 12.51 
 
DOCK1 259 Dedicator of cytokinesis 1 0.02 0.012 0.47 24.22 
 
LTBR 260 Lymphotoxin Beta Receptor 0.02 0.012 0.47 23.49 
 
AIMP2 261 Aminoacyl TRNA Synthetase Complex-Interacting Multifunctional Protein 2 0.02 0.012 0.51 10.21 
 
ABI1 262 Abl Interactor 1 0.02 0.012 0.47 63.72 
 
EPS8L1 263 EPS8 Like 1 0.02 0.012 0.49 26.33 
 
C14ORF145 264 Centrosomal Protein 128 0.03 0.012 0.49 29.98 
 
ZNF827 265 Zinc Finger Protein 827 0.03 0.012 0.53 11.31 
 
DNAJB3 266 DnaJ Heat Shock Protein Family (Hsp40) Member B3 0.03 0.012 0.53 28.51 
 
SOX17 267 SRY-Box 17 0.03 0.012 0.53 47.09 
 
CPNE8 268 Copine 8 0.03 0.012 0.53 13.06 
 
ZNF22 269 Zinc Finger Protein 22 0.03 0.012 0.53 35.94 
 
PEX5 270 Peroxisomal Biogenesis Factor 5 0.03 0.012 0.53 22.84 
 
UTF1 271 Undifferentiated Embryonic Cell Transcription Factor 1 0.03 0.012 0.53 64.52 
 
ADAMTS17 272 ADAM Metallopeptidase With Thrombospondin Type 1 Motif 17 0.03 0.012 0.53 41.73 
 
OAZ3 273 Ornithine Decarboxylase Antizyme 3 0.03 0.012 0.53 18.51 
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 LDHB 274 Lactate Dehydrogenase B 0.03 0.012 0.53 20.18 
 
MTMR1 275 Myotubularin Related Protein 1 0.03 0.012 0.52 29.15 
 
DR1 276 Down-Regulator Of Transcription 1 0.03 0.012 0.52 10.32 
 
POU6F2 277 POU Class 6 Homeobox 2 0.03 0.012 0.52 35.18 
 
LIN54 278 Lin-54 DREAM MuvB Core Complex Component 0.03 0.012 0.52 13.60 
 
RAD51L1 279 RAD51 Paralog B 0.03 0.012 0.52 30.22 
 
SLC25A36 280 Solute Carrier Family 25 Member 36 0.03 0.012 0.52 37.55 
 
RBBP5 281 Retinoblastoma Binding Protein 5 0.03 0.012 0.52 48.22 
 
RAB33B 282 RAB33B, Member RAS Oncogene Family 0.03 0.012 0.52 36.33 
 
NAA38 283 N(Alpha)-Acetyltransferase 38, NatC Auxiliary Subunit 0.03 0.012 0.52 22.43 
 
STXBP3 284 Syntaxin Binding Protein 3 0.03 0.012 0.52 39.95 
 
FAM82A2 285 Regulator Of Microtubule Dynamics 3 0.03 0.012 0.52 29.22 
 
PTPRCAP 286 Protein Tyrosine Phosphatase, Receptor Type C Associated Protein 0.03 0.012 0.52 24.88 
 
STAG3L3 287 Stromal Antigen 3-Like 3 (Pseudogene) 0.03 0.012 0.52 27.11 
 
ADM 288 Adrenomedullin 0.03 0.012 0.52 19.47 
 
CSRP2BP 289 Cysteine And Glycine Rich Protein 2 0.03 0.012 0.52 33.81 
 
FOXP4 290 Forkhead Box P4 0.03 0.012 0.52 30.81 
 
FLYWCH1 291 FLYWCH-Type Zinc Finger 1 0.03 0.012 0.52 55.51 
 
DCTN6 292 Dynactin Subunit 6 0.03 0.012 0.52 39.82 
 
ANPEP 293 Alanyl Aminopeptidase, Membrane 0.03 0.015 0.57 15.18 
 
SORL1 294 Sortilin-Related Receptor, L(DLR Class) A Repeats Containing 0.03 0.012 0.51 14.34 
 
MYBL1 295 MYB Proto-Oncogene Like 1 0.03 0.012 0.51 36.73 
 
CHCHD3 296 Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 3 0.03 0.012 0.51 13.87 
 
CASC5 297 Cancer Susceptibility Candidate 5 0.03 0.012 0.51 56.87 
 
SLC24A2 298 Solute Carrier Family 24 Member 2 0.03 0.012 0.51 26.03 
 
SMNDC1 299 Survival Motor Neuron Domain Containing 1 0.03 0.012 0.51 27.67 
 
KCNQ3 300 Potassium Voltage-Gated Channel Subfamily Q Member 3 0.03 0.012 0.51 35.10 
 
DLD 301 Dihydrolipoamide Dehydrogenase 0.03 0.012 0.51 21.66 
 
ZFP3 302 ZFP3 Zinc Finger Protein 0.03 0.012 0.51 32.84 
 
NDUFB7 303 NADH:Ubiquinone Oxidoreductase Subunit B7 0.03 0.012 0.51 39.76 
 
FBXO34 304 F-Box Protein 34 0.03 0.012 0.51 31.20 
 
ACTR10 305 Actin-Related Protein 10 Homolog 0.03 0.012 0.51 24.05 
 
ZNF365 306 Zinc Finger Protein 365 0.03 0.012 0.51 44.13 
 
TPTEP1 307 Transmembrane Phosphatase With Tensin Homology Pseudogene 1 0.03 0.015 0.51 27.69 
 
VIPR1 308 Vasoactive Intestinal Peptide Receptor 1 0.03 0.012 0.51 18.63 
 
COL12A1 309 Collagen Type XII Alpha 1 0.03 0.012 0.51 26.93 
 
TMC5 310 Transmembrane Channel Like 5 0.03 0.012 0.51 26.85 
 
TSSC1 311 Tumor Suppressing Subtransferable Candidate 1 0.03 0.012 0.51 15.76 
 
EDA 312 Ectodysplasin A 0.03 0.012 0.51 44.32 
 
ABCC5 313 ATP Binding Cassette Subfamily C Member 5 0.03 0.012 0.51 36.80 
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 SPAG6 314 Sperm Associated Antigen 6 0.03 0.012 0.50 35.65 
 
FAM156A 315 Family With Sequence Similarity 156 Member A 0.03 0.012 0.50 19.01 
 
INTS4L1 316 Integrator Complex Subunit 4 Pseudogene 1 0.03 0.012 0.50 19.01 
 
GMFB 317 Glia Maturation Factor Beta 0.03 0.012 0.50 19.20 
 
TSPYL5 318 TSPY-Like 5 0.03 0.012 0.50 22.90 
 
ZDHHC13 319 Zinc Finger DHHC-Type Containing 13 0.03 0.012 0.50 24.60 
 
TAOK2 320 TAO Kinase 2 0.03 0.012 0.50 30.42 
 
ZC3H13 321 Zinc Finger CCCH-Type Containing 13 0.03 0.012 0.50 28.67 
 
PARD3 322 Par-3 Family Cell Polarity Regulator 0.03 0.012 0.50 24.05 
 
CCNG1 323 Cyclin G1 0.03 0.012 0.50 35.58 
 
EPHA7 324 EPH Receptor A7 0.03 0.012 0.50 9.72 
 
SMS 325 Spermine Synthase 0.03 0.012 0.50 16.95 
 
PTPRK 326 Protein Tyrosine Phosphatase, Receptor Type K 0.03 0.012 0.50 39.41 
 
SYNE1 327 Spectrin Repeat Containing Nuclear Envelope Protein 1 0.03 0.012 0.50 39.24 
 
NINL 328 Ninein Like 0.03 0.012 0.50 15.14 
 
DERL2 329 Derlin 2 0.03 0.012 0.50 14.98 
 
DYNC1I2 330 Dynein Cytoplasmic 1 Intermediate Chain 2 0.03 0.012 0.50 21.70 
 
GRIK1 331 Glutamate Ionotropic Receptor Kainate Type Subunit 1 0.03 0.012 0.50 10.52 
 
MEA1 332 Male-Enhanced Antigen 1 0.03 0.012 0.50 15.20 
 
ECHDC2 333 Enoyl-CoA Hydratase Domain Containing 2 0.03 0.012 0.49 10.01 
 
GNAS 334 GNAS Complex Locus 0.03 0.012 0.62 17.57 
 
ZNF583 335 Zinc Finger Protein 583 0.03 0.012 0.61 31.60 
 
ZNF343 336 Zinc Finger Protein 343 0.03 0.014 0.54 16.52 
 
FOXB1 337 Forkhead Box B1 0.03 0.014 0.57 24.81 
 
MBD3L1 338 Methyl-CpG Binding Domain Protein 3 Like 1 0.03 0.015 0.65 16.67 
 
GTF2H2B 339 General Transcription Factor IIH Subunit 2B (Pseudogene) 0.03 0.012 0.52 62.46 
 
ZNF234 340 Zinc Finger Protein 234 0.03 0.012 0.47 34.17 
 
SLC13A3 341 Solute Carrier Family 13 Member 3 0.03 0.012 0.54 20.64 
 
THAP1 342 THAP Domain Containing, Apoptosis Associated Protein 1 0.03 0.012 0.48 61.34 
 
TFCP2 343 Transcription Factor CP2 0.03 0.012 0.47 23.19 
 
HNRNPM 344 Heterogeneous Nuclear Ribonucleoprotein M 0.03 0.012 0.48 29.95 
 
TMEM86B 345 Transmembrane Protein 86B 0.03 0.012 0.48 17.70 
 
SH3BP1 346 SH3 Domain Binding Protein 1 0.04 0.012 0.49 33.77 
 
FAF2 347 Fas Associated Factor Family Member 2 0.04 0.012 0.50 11.30 
 
HSPA4 348 Heat Shock Protein Family A (Hsp70) Member 4 0.04 0.012 0.50 54.57 
 
ACAD11 349 Acyl-CoA Dehydrogenase Family Member 11 0.04 0.012 0.50 44.23 
 
RGS12 350 Regulator Of G-Protein Signaling 12 0.04 0.012 0.50 27.11 
 
EIF4E 351 Eukaryotic Translation Initiation Factor 4E 0.04 0.012 0.50 16.72 
 
GLRX2 352 Glutaredoxin 2 0.04 0.012 0.50 45.60 
 
DAB2IP 353 DAB2 Interacting Protein 0.04 0.012 0.49 22.21 
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 MECOM 354 MDS1 And EVI1 Complex Locus 0.04 0.012 0.49 14.78 
 
CIDEA 355 Cell Death-Inducing DFFA-Like Effector A 0.04 0.012 0.49 36.49 
 
HSBP1 356 Heat Shock Factor Binding Protein 1 0.04 0.012 0.49 19.66 
 
EXOC3L4 357 Exocyst Complex Component 3 Like 4 0.04 0.012 0.49 12.22 
 
APH1A 358 Aph-1 Homolog A, Gamma Secretase Subunit 0.04 0.012 0.49 14.64 
 
PLSCR2 359 Phospholipid Scramblase 2 0.04 0.012 0.49 52.12 
 
ARMC1 360 Armadillo Repeat Containing 1 0.04 0.012 0.49 37.97 
 
BRPF3 361 Bromodomain And PHD Finger Containing 3 0.04 0.012 0.49 27.67 
 
ZNF385B 362 Zinc Finger Protein 385B 0.04 0.012 0.49 42.33 
 
RASA1 363 RAS P21 Protein Activator 1 0.04 0.012 0.49 24.14 
 
BEX5 364 Brain Expressed X-Linked 5 0.04 0.012 0.49 42.62 
 
PPM1H 365 Protein Phosphatase, Mg2+/Mn2+ Dependent 1H 0.04 0.012 0.49 12.04 
 
FUZ 366 Fuzzy Planar Cell Polarity Protein 0.04 0.012 0.49 25.97 
 
MLPH 367 Melanophilin 0.04 0.012 0.49 29.85 
 
NEUROG1 368 Neurogenin 1 0.04 0.012 0.49 35.72 
 
RASGRF1 369 Ras Protein Specific Guanine Nucleotide Releasing Factor 1 0.04 0.012 0.48 29.72 
 
KIF3A 370 Kinesin Family Member 3ª 0.04 0.012 0.48 11.49 
 
GUF1 371 GUF1 Homolog, GTPase 0.04 0.012 0.48 58.19 
 
AQP11 372 Aquaporin 11 0.04 0.012 0.49 27.15 
 
MSTO2P 373 Misato Family Member 2, Pseudogene 0.04 0.012 0.48 70.25 
 
SCOC 374 Short Coiled-Coil Protein 0.04 0.012 0.48 54.22 
 
WWC2 375 WW And C2 Domain Containing 2 0.04 0.012 0.48 34.28 
 
PGAM1 376 Phosphoglycerate Mutase 1 0.04 0.012 0.48 46.40 
 
SLC1A1 377 Solute Carrier Family 1 Member 1 0.04 0.012 0.48 53.79 
 
RASA2 378 RAS P21 Protein Activator 2 0.04 0.012 0.48 53.83 
 
PRR5-ARHGAP8 379 PRR5-ARHGAP8 Readthrough 0.04 0.012 0.48 21.17 
 
ALDH3A2 380 Aldehyde Dehydrogenase 3 Family Member A2 0.04 0.012 0.48 10.56 
 
RHOU 381 Ras Homolog Family Member U 0.04 0.012 0.48 23.16 
 
SPIN3 382 Spindlin Family Member 3 0.04 0.012 0.47 42.43 
 
EPG5 383 Ectopic P-Granules Autophagy Protein 5 Homolog (C. Elegans) 0.04 0.012 0.47 28.66 
 
EHD3 384 EH Domain Containing 3 0.04 0.012 0.47 23.11 
 
LYRM1 385 LYR Motif Containing 1 0.04 0.012 0.47 17.68 
 
TMEM64 386 Transmembrane Protein 64 0.04 0.012 0.47 17.13 
 
MRPS6 387 Mitochondrial Ribosomal Protein S6 0.04 0.012 0.47 30.31 
 
AHCYL1 388 Adenosylhomocysteinase Like 1 0.04 0.012 0.47 63.38 
 
CXCR4 389 C-X-C Motif Chemokine Receptor 4 0.04 0.012 0.47 35.54 
 
GKAP1 390 G Kinase Anchoring Protein 1 0.04 0.012 0.47 51.55 
 
FAM36A 391 COX20 Cytochrome C Oxidase Assembly Factor 0.04 0.012 0.47 47.96 
 
HEATR2 392 HEAT Repeat-Containing Protein 2 0.04 0.012 0.47 19.60 
 
CRELD2 393 Cysteine Rich With EGF Like Domains 2 0.04 0.012 0.47 17.94 
Page 29 of 43 Diabetes
 HACE1 394 HECT Domain And Ankyrin Repeat Containing E3 Ubiquitin Protein Ligase 1 0.04 0.012 0.47 38.01 
 
SIRT1 395 Sirtuin 1 0.04 0.012 0.47 31.12 
 
APEX2 396 Apurinic/Apyrimidinic Endodeoxyribonuclease 2 0.04 0.012 0.47 21.50 
 
NUBP2 397 Nucleotide Binding Protein 2 0.04 0.012 0.47 39.48 
 
PYDC1 398 Pyrin Domain Containing 1 0.04 0.012 0.47 18.93 
 
RBBP7 399 Retinoblastoma Binding Protein 7 0.04 0.012 0.47 34.35 
 
PKHD1L1 400 Polycystic Kidney And Hepatic Disease 1 (Autosomal Recessive)-Like 1 0.04 0.012 0.47 67.86 
 
TNRC18 401 Trinucleotide Repeat Containing 18 0.04 0.012 0.47 34.26 
 
ATRN 402 Attractin 0.04 0.012 0.47 38.27 
 
RGS11 403 Regulator Of G-Protein Signaling 11 0.04 0.012 0.47 22.25 
 
TNFRSF6B 404 Tumor Necrosis Factor Receptor Superfamily Member 6b 0.04 0.012 0.47 23.14 
 
UBQLN4 405 Ubiquilin 4 0.04 0.012 0.48 29.60 
 
C2ORF76 406 Chromosome 2 Open Reading Frame 76 0.04 0.012 0.49 10.08 
 
TBCK 407 TBC1 Domain Containing Kinase 0.04 0.012 0.49 11.81 
 
ZNF711 408 Zinc Finger Protein 711 0.04 0.012 0.49 22.41 
 
FRG1 409 FSHD Region Gene 1 0.04 0.012 0.49 20.34 
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Supplemental Table 2. Gene Ontology (GO) analysis of differentially methylated genes 
(n=409). Significant enriched components are grouped according to three categories:  
(a) Biological Processes; (b) Molecular function; and (c) Cellular components.  
 
 
 
 
 
 
 
 
 
 
 
 Included Genes P-value 
(a) Biological Processes   
Intracellular signalling cascade 12 5.12E-05 
Regulation of metabolic processes 121 6.1E-05 
Cell development 7 7.35E-05 
Cell Morphogenesis 32 3.7E-04 
Embryonic Organ Development 15 4.9E-04 
Macromolecule Biosynthesis 117 2.5E-04 
(b) Molecular functions   
DNA Binding 266 1.1E-04 
Transcription regulation 89 4.7E-04 
(c) Cellular components   
Integral to membrane organization 7 4.5E-04 
Intrinsic to plasma membrane 3 2.2E-04 
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Supplemental Table 3. Top-ranked (p<0.009) differentially hypermethylated genes included in the canonical pathways categorized by P value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *The most relevant functions of each gene are emphasized 
†
Analyzed by pyrosequencing 
‡ 
Validated by pyrosequencing 
  
 
Gene Symbol  Gene Denomination 
Chromosome Location &  
Number of CPG Islands 
Function* P value 
NKX6-1
†‡
 NK6 homeobox 1 Chr 4, bp 85417332-85419573 (5 CpG) β cell development and function 0.0002 
CHRM2 Cholinergic receptor, muscarinic 2 Chr 7; bp 136553436-136557857 (3 CpG) Cardiac function 0.0008 
LMO2 LIM domain only 2 (rhombotin-like 1) Chr 11; bp 33889459-33891595 (4 CpG) Red blood cell development 0.001 
ATG2B
†‡
 Autophagy related 2B Chr 14, bp 96828029-96832550 (4 CpG) Autophagy and energy homeostasis 0.002 
MLLT3 Myeloid/lymphoid or mixed-lineage leukemia: translocated to, 3 Chr 9; bp 20616942-20625657 (4 CpG) Transcription regulation 0.002 
CLSTN2 Calsyntenin 2 Chr 3; bp 139652460-139654727 (4 CpG) Neural function 0.002 
KLF11
†
 Kruppel-like factor 11 Chr 2, bp 10180437-10189152 (4 CpG) Apoptosis 0.003 
SLC13A5
†‡
 Sodium-dependent citrate transporter, member 5 Chr 17, bp 6614780-6619231 (5 CpG) Lipid metabolism 0.003 
NRIP1
†
 Nuclear receptor interacting protein 1 Chr 21, bp 16434348-16438687 (6 CpG) Transcription regulation, myogenesis 0.003 
ZNF500 Zinc finger protein 500 Chr 16; bp4815731-4817858 (5 CpG) Transcription regulation 0.003 
GFOD1 Glucose-fructose oxidoreductase domain containing 1 Chr 6; bp 13486105-13488206 (4 CpG) Nucleotide binding 0.004 
LRP10 Low density lipoprotein receptor-related protein 10 Chr 4; bp 46938324-46940419 (4 CpG) Internalization of lipophilic molecules 0.004 
GTF2H2C General transcription factor IIH, polypeptide 2C Chr 5; bp 68855809-68856161 (4 CpG) Transcription regulation  0.004 
PYGO2 Pygopus family PHD finger 2 Chr1; bp154933928 – 154934735 (3 CpG) Signal transduction 0.004 
ZGPAT Zinc finger, CCCH-type with G patch domain Chr 20; bp 62339083-62341337 (4 CpG) Transcription repressor 0.005 
KCNK13 Potassium channel, subfamily K, member 13 Chr 14; bp90526475-90528701 (6 CpG) Neural and heart metabolism 0.005 
SOGA1 Suppressor of glucose, autophagy associated 1 Chr 20; bp 35489914-35492105 (5 CpG) Autophagy 0.005 
CALHM2 Calcium homeostasis modulator 2 Chr 10; bp 105195805-105204248 (5 CpG) Calcium metabolism 0.006 
SKAP2 Src kinase associated phosphoprotein 2 Chr 7; bp 26903474-26905663 (3 CpG) Src signaling pathway 0.006 
KPNA4 Karyopherin alpha 4 (importin alpha 3) Chr 3; bp 160282616-160284700 (4 CpG) Nuclear protein import 0.006 
FMR1 Fragile X mental retardation 1 Chr X: bp146992741-146994927 (5 CpG) Translation repressor 0.007 
NKX2-5 NK2 Homeobox 5 Chr 5; bp 172662964-172665144 (4 CpG) Heart development 0.008 
ZNF182 Zinc finger protein 182 Chr 7; bp 148934520-14893861 (4 CpG) Transcription regulation 0.008 
ZNF436 Zinc finger protein 436 Chr 1; bp 23693745-23695831 (4 CpG) Transcription regulation 0.008 
ICOSLG Inducible T-cell co-stimulator ligand Chr 21; bp 45660794-45663032 Inflammation 0.008 
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 Supplemental Table 4. Top-ranked (p<0.009) differentially hypomethylated genes included in the canonical pathways categorized by P value.  
 
 
*The most relevant functions of each gene are emphasized 
† 
Analyzed by pyrosequencing  
‡ 
Validated by pyrosequencing 
 
 
Gene Symbol  Gene Denomination 
Chromosome Location &  
Number of CPG Islands 
Function* P value 
HIST1H2BI Histone cluster 1, H2bi Chr 6; bp 26272470-26272696 (1 CpG) Transcription regulation, DNA repair and DNA replication 0.0002 
UHRF2  Ubiquitin-like with PHD and ring finger domains 2, E3 ubiquitin protein ligase Chr 9; bp 6411295-6413552 (4 CpG) Cell cycle regulation 0.0003 
MAPK8IP1
†
 Mitogen-activated protein kinase 8 interacting protein 1 Chr 11; bp 45906583-45908717 (3 CpG) Pancreatic β-cell regulation 0.0004 
CAMK4 
†
 Calcium/calmodulin-dependent protein kinase IV Chr 5; bp 110558538-110560607 (4 CpG) Regulation of glucose metabolim 0.0004 
TOP3B Topoisomerase (DNA) III beta Chr 22; 22336948 – 22337333 (1 CpG) DNA recombination and genome stability 0.001 
STARD3NL STARD3 N-terminal like Chr 7; bp 38216648-38218788 (5 CpG) Intracellular transport of cholesterol and sphingolipids  0.001 
EIF2AK1 Eukaryotic translation initiation factor 2-alpha kinase 1 Chr 7; bp 6097361-6099530 (7 CpG) Translational inhibitor 0.002 
SFPQ Splicing factor proline/glutamine-rich Chr 1; bp 35657482-35659727 (8 CpG) Post-transcriptional regulation 0.002 
DOCK5 Dedicator of cytokinesis 5 Chr 8; bp 25041795-25042820 (1 CpG) Guanine nucleotide exchange  0.003 
GPR120 
†‡
 Free fatty acid receptor 4 Chr 10, bp 95325316-95327446 (4 CpG) Lipid metabolism 0.003 
PEX1 Peroxisomal biogenesis factor 1 Chr 7; bp 92157487-92158405 (1 CpG) Peroxisomal transport  0.004 
PRKG1 Protein kinase, cGMP-dependent, type I Chr 6; bp 52750229-52752471 (6 CpG) Cardiovascular and neuronal regulator 0.004 
NKX3-2 NK3 homeobox 2 Chr 4; bp 13532661-13534792 (3 CpG) Skeletal development 0.004 
MAPK13 Mitogen-activated protein kinase 13 Chr 6; bp 36097402-36099496 (6 CpG) Extracellular signaling 0.005 
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Materials 
Subjects Inclusion and Exclusion criteria 
Inclusion criteria were: 
• Infants born from a singleton term pregnancy (37–42 wk) at Hospital Sant Joan de 
Déu, Barcelona; birth weight between 2.9 and 3.8 Kg for AGA infants (Z-scores 
between -1.1 and +1.1 for gestational age and sex), and between 1.9 and 2.6 Kg for 
SGA infants (Z-score below -2.0), as to obtain two distinct study subpopulations 
(Ferrández-Longás A, Mayayo E, Labarta JI, Bagué L, Puga B, Rueda C, Ruiz-
Echarri M, Labena C. Estudio longitudinal de crecimiento y desarrollo. Centro 
Andrea Prader. Zaragoza 1980-2002. In ERGON, ed. Patrones de crecimiento y 
desarrollo en España. Atlas de gráficas y tablas, pp 61-115. Madrid: 2004; Clayton 
PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management 
of the child born small for gestational age through to adulthood: a consensus 
statement of the International Societies of Pediatric Endocrinology and the Growth 
Hormone Research Society. J Clin Endocrinol Metab 2007; 92:804-810). 
• Placenta collected at delivery for research purposes; the inclusion rate was limited 
by logistic restraints (in particular for overnight collection).  
• Written, informed consent in Spanish/Catalan language by at least one parent. 
Exclusion criteria were: 
• Maternal hypertension, pre-eclampsia, gestational diabetes [two or more altered 
values in the oral glucose tolerance test in the second trimester], alcohol abuse, 
smoking, or drug addiction. 
• Birth weight below 1.9 Kg, since these infants are usually admitted to the Neonatal 
Unit.  
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 2 
• Complications at birth (need for resuscitation or parenteral nutrition), congenital 
malformations, or a syndromic or infectious etiology of low birth weight.  
 
Cord blood and placenta collection 
Venous cord blood was collected and processed before the separation of the 
placenta (López-Bermejo A, Petry CJ, Diaz M, Sebastiani G, de Zegher F, Dunger DB, 
Ibáñez L. The association between the FTO gene and fat mass in humans develops 
within two weeks after birth. J Clin Endocrinol Metab 2008; 93:1501-1505) and frozen 
at -80ºC until assay. After delivery, placentas were weighed and biopsies were then 
obtained from the maternal side, as described (Díaz M, Bassols J, Lopez-Bermejo A, 
Gomez-Roig MD, de Zegher F, Ibáñez L: Placental expression of peroxisome 
proliferator-activated receptor-γ: relation to placental and fetal growth. J Clin 
Endocrinol Metab 2012; 97: E1468–1472). We elected to assess the maternal side of 
the placenta because changes in epigenetic marks are expected to occur first in those 
cells rather that in placental fetal cells, in order to counteract a reduced nutrient supply. 
We followed a rigorous protocol aiming for sample uniformity in type and number of 
cells. Briefly, placentas were sectioned 4 cm around umbilical’s cord insertion 
removing the amniotic and chorionic layers and obtaining fragments of about 1 cm
3
 that 
were immediately rinsed three times in saline buffer to remove blood cells. To avoid 
degradation, biopsies were obtained within 5 minutes of delivery and were ultrafrozen 
in liquid nitrogen before storage at -80°C until DNA and RNA extraction.  
 
DNA extraction and modification 
DNA was extracted from placenta and cord blood samples by the phenol-
chloroform method (Promega, Madison, Wisconsin, USA), following the 
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manufacturer’s protocols. DNA quality and concentration were assessed using a UV-
VIS spectrophotometer (Nanodrop 1000, Agilent Technologies, Wilmington, DE, 
USA); 300 ng of placental and cord blood DNA were bisulfite-modified using the 
Methylcode Bisulfite Conversion Kit (Invitrogen, Carlsbad, CA, USA) following 
manufacturer’s guidelines. 
 
Microarray data pre-processing 
Probe intensities were extracted from scan images as raw signals with no 
background subtraction, using Agilent’s Feature Extraction Software (v.10.7). The raw 
data were imported into Agilent Genomic Workbench v6.5 BATMAN algorithm 
(Bayesian Tool for Methylation Analysis), and normalized to control probes present on 
the array. Outlier features on the arrays were flagged by the same software package. 
Values were log2-transformed and logged data were used for principal component 
analysis (PCA) (data not shown), and for statistical analysis. The Welch T-test was used 
for identification of differentially methylated genes. An individual probe was 
considered differentially methylated if its p-value was < 0.05 (not corrected for multiple 
testing), and if the associated difference of means between the AGA and SGA 
subgroups was at least 0.25. The resulting P values for each gene were then corrected 
for multiple testing by calculating their false discovery rate (FDR). A gene promoter 
was considered differentially methylated if its FDR was < 0.1. To investigate the 
biological relevance of these genes, we performed a Gene Ontology (GO) analysis 
(http://www.geneontology.org). Significantly enriched (p<0.01) GO terms in SGA 
versus AGA newborns were obtained and subdivided into three categories “Biological 
Processes”, “Molecular functions”, and “Cellular components”. Gene networks and 
canonical pathways representing key genes were identified using the KEGG (Kyoto 
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Encyclopedia of Genes and Genomes) software (Altman T, Travers M, Kothari A, Caspi 
R, Karp PD. A systematic comparison of the MetaCyc and KEGG pathway databases. 
BMC Bioinformatics 2013;14:112).   
Validation of DNA methylation patterns by pyrosequencing (see below) was 
limited to n=8 genes: GPR120 (G-protein coupled receptor 120), ATG2B (autophagy-
related 2B), NKX6.1 (NKX6 homeodomain 1), SLC13A5 (Mammalian Indy 
homologue), KLF11 (Kruppel-like factor 11), NRIP1 (Nuclear receptor interacting 
protein 1); MAPK8IP1 (mitogen-activated protein kinase 8 interacting protein 1) and 
CAMK4 (Calcium/Calmodulin-Dependent Protein Kinase IV). The rationale as well as 
the subsequent steps undertaken to come to this selection are detailed in the Results 
section. 
 
Validation of DNA-methylation patterns by bisulfite pyrosequencing  
Specific pyrosequencing primers and pre-designed PCR primers for 
quantification of CpG methylation (Qiagen, Germantown, USA) were used for 
validation in the 51 placenta-cord blood pairs (30 AGA; 21 SGA), selecting primers 
flanking the same CpG islands assessed in the array from the promotor regions of the 
following loci: MAPK8IP1 (PM00152586), chr 11, bp 45906583-45908717 (3 CpG 
sites); CAMK4 (PM00117530), chr 5, bp 110558538-110560607 (4 CpG sites); 
GPR120 (PM00044758), chromosome 10, bp 95325316-95327446 (4 CpG sites); 
ATG2B (PM00164570), chr 14, bp 96828029-96832550 (4 CpG sites); KLF11 
(PM00011942), chr 2, bp 10180437-10189152 (4 CpG sites); NKX6.1 (PM00019299), 
chr 4, bp 85417332-85419573 (5 CpG sites); NRIP1 (PM00203259), chr 21, bp 
16434348-16438687 (6 CpG sites); SLC13A5 (PM00067039), chr 17, bp 6614780-
6619231 (5 CpG sites). We used 1 µl of bisulfite- converted DNA as template for each 
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PCR in a final volume of 25 µl. Hot-start PCR was performed using the PyroMark PCR 
kit (Qiagen, Germantown, USA) and the correct size of the PCR product was verified 
by gel electrophoresis. Pyrosequencing was performed using the PyroMark Q96 ID 
system and evaluated using the PyroMark software 2.5 (Qiagen, Germantown, USA). 
The target CpG sites were evaluated by converting the resulting pyrograms to numerical 
values for peak heights. The methylation percentage of each locus was calculated as the 
mean of all CpG analyzed.  
 
RNA isolation and retro-transcription 
Between 100 and 125 mg of frozen placenta was homogenized using a Polytron 
benchtop homogenizer (Kinematica Ag, Littau-Luzern, Switzerland). Total RNA was 
isolated from placental homogenates and from 1 mL cord blood samples using Tripure 
reagent (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer’s 
protocol. The quantity of isolated RNA was determined with a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). In addition, 1 µg 
of total RNA was run on a 1.0% agarose gel using SYBR safe staining to test the 
integrity of the RNA. Samples with partially degraded RNA (n=8) were rejected. 2 µg 
of total RNA was reverse-transcribed to cDNA using the high capacity RNA-to-cDNA 
kit (Applied Biosystems, Foster City, CA, USA), and subsequently diluted with 
nuclease-free water (Sigma, St. Louis, MO, USA) to a concentration of 20 ng/µl cDNA. 
Retrotranscription products were stored at -20ºC until use. 
 
Assays & Neonatal Body Composition 
Circulating glucose was measured by glucose oxidase method. Insulin and IGF-I 
were assessed by immuno-chemiluminescence (DPC IMMULITE 2500, Siemens, 
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Germany), the respective detection limits being 0.4 µU/mL and 25 ng/mL; intra- and 
inter-assay coefficients of variation (CV’s) were <10%. Circulating HMW adiponectin 
was measured with an ELISA kit (R&D Systems, Minneapolis, MN, USA); intra- and 
inter-assay CVs were <9%. Samples were stored at -20ºC until assay. 
Body composition was assessed at the neonatal age of approximately 2 weeks 
(range, 11-17 days), by dual X-ray absorptiometry with a Lunar Prodigy, coupled to 
Lunar software (Lunar Corp, Madison, WI), adapted for assessment of infants; body fat 
and lean mass were assessed during natural sleep; coefficients of variation (CVs) were 
<3% for lean and fat mass (Ref. 4 of the manuscript). 
 
Data 
Correlation analyses 
Cord blood glucose showed a positive correlation with insulin levels (r=0.35; 
p=0.01). No correlations were found between maternal BMI, cord blood insulin, and 
body composition in infants.  
In placenta, hypermethylation in ATG2B, NKX6.1 and SLC13A5, and 
hypomethylation in GPR120 associated with lower birth weight, birth length, lean mass 
and circulating IGF-I (P<0.04 to P<0.0001), and to less total and abdominal fat at 2 
weeks (P<0.02 to P<0.0001). These associations were essentially the same in cord blood 
(all P<0.01 to P<0.0001) (Supplemental Table 5). 
 In placenta, lower expression of ATG2B, NKX6.1 and SLC13A5, and higher 
expression of GPR120 associated with lower birth weight, birth length, total and 
abdominal fat (P<0.03 to P<0.0001). In cord blood, expression levels of GPR120, 
NKX6.1 and SLC13A5 were positively associated with birth weight and serum IGF-I 
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(P<0.01 to P<0.0001) while those of GRP120 and SLC13A5 directly correlated with 
total and abdominal fat (P<0.003 to P<0.0001) (Supplemental Table 5).  
All correlations were maintained after adjusting for sex, gestational age, type of 
delivery and pre-gestational BMI.  
  
Multiple regression analyses 
Multivariate analysis  adjusting for sex and gestational age showed that birth 
weight was independently explained by GPR120 methylation (β=0.558, P<0.001) and 
both NKX6.1 methylation and expression in placenta (β=-0.294, P=0.02; β=0.484, 
P<0.001, respectively) (Supplemental Table 6a). In cord blood, GPR120 methylation 
explained 49% of birth weight variability (β=-0.699, P<0.001) (Supplemental Table 6b). 
 In addition, total and abdominal fat at age 2 weeks were independently explained 
by placental GPR120 and SLC13A5 methylation (β =0.771, P<0.001; β =0.400, P=0.03 
for total fat; β= 0.748, P<0.001; β=0.511, P=0.008 for abdominal fat, respectively) and 
by placental NKX6.1 expression (β=0.442, P=0.006 for total fat; β=0.509, P=0.002 for 
abdominal fat) (Supplemental Table 7a). In cord blood, GPR120 expression was the 
only predictor of total and abdominal fat (β=0.413, P=0.01, and β=0.330, P=0.04, 
respectively) (Supplemental Table 7b). 
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Supplemental Table 5. Bivariate correlations between placental and cord blood gene 
methylation and expression and selected parameters in all subjects. 
 
 
 
 
IGF-I: insulin-like growth factor I 
 
 
 
 
 
 
Methylation  Expression 
 Placenta Cord Blood  Placenta Cord Blood 
ATG2B β P β P  β P β P 
Birth weight -0.316 0.03 -0.441 0.002  0.522 <0.0001 - - 
Birth length -0.358 0.013 -0.435 0.002  0.495 <0.0001 - - 
IGF-I -0.293 0.045 - -  - - 0.338 0.023 
Fat Mass - - - -  0.442 0.001 - - 
Abdominal fat - - - -  0.416 0.003 - - 
Lean Mass -0.334 0.022 -0.509 <0.0001  0.428 0.002 - - 
NKX6          
Birth weight -0.358 0.025 -0.593 <0.0001  0.553 <0.0001 0.399 0.007 
Birth length -0.395 0.001 -0.581 <0.0001  0.473 <0.0001 0.329 0.027 
Insulin - - -0.310 0.046  - - - - 
IGF-I -0.328 0.002 -0.420 0.003  0.448 0.001 0.327 0.028 
Fat Mass -0.492 0.001 - -  0.324 0.02 - - 
Abdominal fat -0.417 0.008 -0.313 0.031  0.325 0.02 - - 
Lean Mass -0.324 0.044 -0.560 <0.0001  0.476 <0.0001 - - 
SLC13A5          
Birth weight -0.560 <0.0001 -0.505 <0.0001  0.415 0.002 0.661 <0.0001 
Birth length -0.463 0.001 -0.477 0.001  0.498 <0.0001 0.597 <0.0001 
Insulin - - -0.330 0.031  - - 0.346 0.027 
IGF-I -0.393 0.004 -0.360 0.0011  0.386 0.005 0.629 <0.0001 
Fat Mass -0.313 0.025 - -  0.458 0.001 0.435 0.003 
Abdominal fat -0.358 0.01 -0.305 0.033  0.488 <0.0001 0.410 0.005 
Lean Mass -0.557 <0.0001 -0.512 <0.0001  0.430 0.002 0.647 <0.0001 
GPR120          
Birth weight 0.642 <0.0001 -0.621 <0.0001  -0.421 0.002 0.378 0.012 
Birth length 0.592 <0.0001 -0.621 <0.0001  -0.407 0.003 - - 
Insulin 0.349 0.019 -0.325 0.036  - - - - 
IGF-I 0.475 <0.0001 -0.414 0.004  - - 0.445 0.004 
Fat Mass 0.615 <0.0001 - -  -0.295 0.038 0.514 <0.0001 
Abdominal fat 0.588 <0.0001 -0.369 0.011  -0.421 0.002 0.431 0.003 
Lean Mass 0.617 <0.0001 -0.615 <0.0001  -0.309 0.029 0.320 0.034 
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Supplemental Table 6. Multivariate linear models of birth weight in placenta (a) and cord 
blood (b). 
 
 
 
 
 
 
 
(a) Non-predictive variables: sex, maternal body mass index (BMI), ATG2B methylation, 
ATG2B expression, SLC13A5 methylation, SLC13A5 expression and GPR120 expression.  
 
(b) Non predictive variables: sex, maternal body mass index (BMI), GPR120 expression, 
ATG2B methylation, ATG2B expression, SLC13A5 methylation and  SLC13A5 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
Placenta 
 
Birth weight 
Beta Sig. R2 
GPR120 methylation 0.558 <0.001 30% 
NKX6.1 methylation -0.294 0.02 62% 
NKX6.1 expression 0.484 <0.001 54% 
(b) 
Cord Blood Birth weight 
Beta Sig. R
2
 
GPR120 methylation -0.699 <0.001 49% 
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Supplemental Table 7. Multivariate linear models of fat and abdominal fat mass at age 2 
weeks in placenta (a) and cord blood (b). 
 
 
 
 
 
 
 
 
 
(a) Non-predictive variables: sex, maternal body mass index (BMI), GPR120 expression, 
SLC13A5 expression, NKX6.1 methylation, ATG2B methylation or expression.  
 
(b) Non-predictive variables: sex, maternal body mass index (BMI), GPR120 methylation, 
SLC13A5 methylation or expression, NKX6.1 methylation or expression, ATG2B methylation or 
expression. 
 
(a) 
Placenta Total Fat (g)  Abdominal Fat 
Beta Sig. R2 Beta Sig. R2 
GPR120 methylation 0.771 <0.001 30% 0.748 <0.001 22% 
SLC13A5 methylation 0.400 0.03 51% 0.511 0.008 51% 
NKX6.1 expression 0.442 0.006 41% 0.509 0.002 35% 
(b) 
Cord Blood 
 
Total Fat (g)  Abdominal Fat 
Beta Sig. R
2
 Beta Sig. R
2
 
GPR120 expression 0.413 0.01 17% 0.330 0.04 11% 
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